scPharmaceuticals Stock (NASDAQ:SCPH)
Previous Close
$3.52
52W Range
$3.08 - $6.71
50D Avg
$4.42
200D Avg
$4.71
Market Cap
$168.13M
Avg Vol (3M)
$350.24K
Beta
0.14
Div Yield
-
SCPH Company Profile
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
SCPH Performance
Peer Comparison
| Ticker | Company |
|---|---|
| MNPR | Monopar Therapeutics Inc. |
| CNTA | Centessa Pharmaceuticals plc |
| IOVA | Iovance Biotherapeutics, Inc. |
| KTTA | Pasithea Therapeutics Corp. |
| MCRB | Seres Therapeutics, Inc. |
| SCPS | Scopus BioPharma Inc. |
| ONCY | Oncolytics Biotech Inc. |
| DMAC | DiaMedica Therapeutics Inc. |
| MIST | Milestone Pharmaceuticals Inc. |
| LIFE | aTyr Pharma, Inc. |
| LYRA | Lyra Therapeutics, Inc. |